Author: Vivian Xie 8th July 2026

The international pharma industry is facing a paradigm shift when it comes to the way medication is packaged. Traditionally, materials like petroleum-based plastics have been the bedrock of pharmaceutical packaging; however, with the pharmaceutical sector generating an annual estimate of 52 million metric tonnes [1] of CO₂ from its packaging-related activities, the sector’s environmental responsibilities are now essential to operations, with companies already pivoting towards actionable sustainability solutions.

The market for sustainable pharmaceutical packaging has demonstrated substantial growth trajectories, projected to be worth USD 55.87 billion by 2035, [2] at a 5.55% CAGR. In this global context, the Asia-Pacific region has emerged as a focal point for innovation and implementation in the move towards sustainable pharmaceutical packaging solutions. Driven by governmental environmental regulations, expanding pharmaceutical manufacturing capacity and export market compliance requirements, markets like China and India have accelerated their adoption [3] of sustainability measures.

Here, we’ll explore the circumstances that led to these changes, and what industry leaders in the Asia-Pacific are doing to stay at the forefront of sustainable pharmaceutical packaging.

How Has Asia Demonstrated Commitment to Sustainability in Pharmaceutical Packaging

Regulatory Frameworks and Policy Drivers

Across the continent, Asian governments have put increasingly stringent environmental regulations in place, mandating reductions in plastic waste, enhanced recycling protocols, and limitations on carbon emissions. These regulatory changes have compelled packaging manufacturers to transition towards eco-friendly pharma materials, while maintaining compliance with existing global pharmaceutical quality standards. [4]

The regulatory landscape in the Asia-Pacific reflects the dual imperatives of environmental compliance and pharmaceutical safety. Governments across ASEAN nations have begun implementing Extended Producer Responsibility (EPR) schemes and packaging material restrictions, creating a favourable policy environment for sustainable packaging innovation. [5] Concentrated in major manufacturing centres like Shanghai, Beijing, Guangzhou, and Jiangsu Province, China's pharmaceutical sector has witnessed widespread adoption of recyclable packaging materials, providing easier access to export markets and strengthening compliance with new and existing regulations.

Southeast Asia’s pharmaceutical packaging sector is likewise undergoing fundamental transformations driven by comprehensive sustainability regulations. Singapore has implemented its Mandatory Packaging Reporting (MPR) Scheme, [6] requiring companies with annual turnover exceeding S$10 million to report packaging data and reduce, reuse, and recycle plans through the Waste & Resource Management System, whilst the Health Sciences Authority is actively encouraging transitions towards recyclable materials aligned with Singapore’s Zero Waste Masterplan launched in August 2019.

Countries like Vietnam and Thailand are also effectively enacting similar legislation to the Extended Producer Responsibility, mandating producers and importers to manage the collection, recycling, and waste treatment of packaging materials, [7] and pilot programmes operating in places like Chonburi, Thailand to expand material scope [8] and restrict PFAS concentrations, among other regulatory guidance.

Market Dynamics and Growth Trajectories

China leads the pack when it comes to the region’s sustainable transformation, with a projected CAGR of 16.5% through 2035, and at 15.8%, India is not far behind. Both countries are supported by an expanding capacity for pharmaceutical production and appealing government incentives for environmental initiatives.

There are several converging factors underpinning this growth: [9] in particular, escalating environmental concerns, stricter regulatory frameworks, growing consumer demand for sustainable products, and technological advancements have created a situation where safer, more durable solutions can be found. However, the challenge of balancing sustainability with patient safety remains. Pharmaceutical packaging must provide high protective barriers, sterilisation compatibility, and chemical stability; this has previously been provided by traditional multilayer plastics and aluminium, materials which are increasingly difficult to recycle. That puts financial pressure on the R&D facilities charged with identifying sustainable alternatives that satisfy both environmental and pharmaceutical regulatory standards.

Asia’s Most Promising Bio-Based and Recyclable Materials

Biodegradable Pharmaceutical Packaging Developments

Derived from renewable sources, bio-based materials include cellulose, plant-based polymers and compostable films, and are seeing rising use in packaging that does not come into direct contact with medications. These materials reduce the supply chain’s carbon footprint, and are more biodegradable than conventional petroleum-based plastics.

These modern biodegradable packaging materials are durable, safe and cost-effective, and the market for these solutions is projected to reach US$17.87 billion by 2035. As AI becomes further integrated into the development of these materials, the innovation timeline will continue to accelerate, letting manufacturers design packaging that minimises ecological impact without compromising safety or efficacy.

Recyclable and Post-Consumer Recycled Materials

The adoption of Post-Consumer Recycled (PCR) plastics represents a pragmatic approach to sustainable pharmaceutical packaging. PCR materials are manufactured from recycled consumer plastic waste, then refined and reprocessed into quality packaging materials suitable for pharmaceutical applications where regulatory guidelines permit. Examples include Singapore's Health Sciences Authority encouraging transitions towards recyclable materials aligned with the nation's Zero Waste Masterplan [10] launched in August 2019, and Vietnam's EPR legislation [11] mandating that producers manage collection and recycling of packaging materials.

This approach supports circular economy principles, prioritising the reuse of materials to reduce environmental harm and lower the reliance on and consumption of new plastic products. Recyclable packaging has also emerged as a dominant part of the sustainable pharmaceutical packaging market, thanks to plastic’s existing prevalence in the process. The recyclable process segment [12] led the market in 2024, reflecting industry recognition that effective recycling infrastructure is essential for sustainability. Meanwhile, monomaterial packaging designs, which are constructed from single materials such as recycled polyethylene terephthalate (PET) or certified cardboard, help to streamline recycling measures [13] and reduce industry waste.

Advanced Barrier Materials and Smart Packaging Integration

Asia’s innovation in green packaging extends beyond replacing traditional materials, encompassing intelligent packaging platforms with embedded tracking capabilities, material composition optimisation and lifecycle impact modelling. These integrations enable proactive approaches to environmental management, prioritising material selection and minimising waste. Smart packaging technologies combine sustainability with functionality, incorporating features such as tamper-evident systems, child-resistant designs and advanced barrier materials for drug protection.

Balancing Sustainability with Product Protection and Compliance

Regulatory Compliance Requirements

Pharmaceutical packaging must meet a range of regulatory requirements established by international authorities. WHO guidelines stipulate that packaging has to shield drugs from chemical, biological and physical contamination, with special attention needing to be paid to maintaining the integrity of sterile products. The FDA's guidance on container closure systems [14] for packaging human drugs and biologics specifies that materials must not be reactive, additive or absorptive in ways that alter the safety, identity, strength, quality or purity of the drug beyond established requirements.

EMA guidance [15] lays out requirements for selection, testing, and quality control of any plastic materials used in pharmaceutical packaging, avoiding any adverse interactions with drug product and maintaining stability and efficacy throughout their shelf life. ISO 15378:2017 provides an internationally recognised standard [16] for quality management systems in the production of primary packaging materials, combining ISO 9001 quality management principles with Good Manufacturing Practices specific to pharmaceutical packaging.

Material Performance and Safety Considerations

Sustainable packaging materials must demonstrate equivalent or superior performance characteristics to traditional materials across multiple parameters: barrier properties against moisture, oxygen and light; mechanical strength and durability; chemical compatibility with pharmaceutical products; and sterility maintenance for parenteral formulations. Transitioning to sustainable materials requires comprehensive testing protocols to be put into place, including material assessment, extractables and leachables studies, barrier property evaluation, compatibility studies and stability and microbial testing.

The challenge of maintaining pharmaceutical product integrity whilst employing sustainable materials requires rigorous validation. Testing for extractables and leachables (compounds that can migrate from packaging into drug products) represents a critical safety consideration. Both EMA and FDA mandate comprehensive testing to identify potential contaminants and assess their impact on drug safety and efficacy.

The Packaging Materials Zone at Pharmapack Asia 2026

Launching in Singapore in November 2026, Pharmapack Asia expands the established European platform into the Asia-Pacific region. This inaugural event is set to provide a world-class platform for stakeholders across the drug delivery and packaging supply chain to connect, collaborate, and showcase innovations tailored to the evolving needs of the Asian market. [15] The choice of Singapore to host the show reflects its position as a regional hub for high-value drugs, complex manufacturing and pharmaceutical innovation, supported by world-class infrastructure that facilitates regional distribution.

The Packaging Materials Zone will serve as the show’s focal point for sustainable packaging innovation, featuring developments in eco-friendly packaging solutions, smart packaging technologies, child-resistant designs, tamper-evident systems and advanced barrier materials for drug protection. The zone is designed to facilitate connections between pharmaceutical manufacturers, packaging engineers, regulatory affairs professionals, quality assurance managers and procurement specialists involved in drug packaging decisions.

With over 2,500 attendees expected to attend, alongside 120+ exhibiting companies and participants from more than 40 countries, the event will showcase global innovations across packaging and contract manufacturing, with particular emphasis on sustainable solutions and cutting-edge technologies shaping the pharmaceutical packaging industry.

The transformation of pharmaceutical packaging towards sustainability represents a complex undertaking that requires simultaneous advancement across multiple dimensions: material science innovation, regulatory compliance, manufacturing process optimisation and supply chain integration. Asian pharmaceutical companies and packaging manufacturers have demonstrated leadership in this transition, driven by supportive governmental policies, substantial market growth and technological innovation.

Future developments will likely focus on continued material innovation, including algae-based plastics and bio-derived polymers, alongside advancements in recycling technologies that facilitate processing of complex pharmaceutical packaging. The integration of circular economy principles, wherein materials are systematically reused and recycled, represents the ultimate objective of sustainable pharmaceutical packaging.